Perilipin, also known as lipid droplet-associated protein, perilipin 1, or PLIN, is a
protein that, in humans, is encoded by the PLINgene.[5] The perilipins are a family of proteins that associate with the surface of
lipid droplets. Phosphorylation of perilipin is essential for the mobilization of fats in adipose tissue.[6]
Perilipin family of proteins
Perilipin is part of a gene family with six currently-known members. In
vertebrates, closely related genes include
adipophilin (also known as adipose differentiation-related protein or Perilipin 2),
TIP47 (Perilipin 3),
Perilipin 4 and Perilipin 5 (also called MLDP, LSDP5, or OXPAT). Insects express related proteins,
LSD1 and
LSD2, in fat bodies.[7] The yeast Saccharomyces cerevisiae expresses PLN1 (formerly PET10), that stabilizes lipid droplets and aids in their assembly.[8]
Evolution
The perilipins are considered to have their origins in a common ancestral gene which, during the first and second vertebrate genome duplication, gave rise to six types of PLIN genes.[9]
Composition and structure
Human perilipin
Human perilipin-1 is composed by 522
amino acids, which add up to a molecular mass of 55.990 kDa. It presents an estimated number of 15 phosphorylation sites (residues 81, 85, 126, 130, 132, 137, 174, 299, 301, 382, 384, 408, 436, 497, 499 and 522)[11] from which 3 -those in bold- have been suggested to be relevant for stimulated-lipolysis through PKA phosphorylation - they correspond respectively to PKA Phosphorylation sites 1, 5 and 6.[12] A compositional bias of
Glutamic acid can be found between residues 307 and 316.[13] Its
secondary structure has been suggested to be conformed exclusively by partially hydrophobic
α-helixes,[10] as well as the respective coils and bends.
Whereas perilipin-1 is coded by a single gene, alternative
mRNA splicing processes can lead to three
protein isoforms (Perilipin A, B and C). Both Perilipin A and B present common N-terminal regions, differing in the C-terminal ones.[14] Concretely, beginning from the N-terminal of Perilipin-1, a PAT domain—characteristic of its protein family—can be found, followed by an also characteristic repeated sequence of 13 residues which form
amphipathic helixes with an active role in linking membranes[15] and a 4-helix bundle before the C-terminal carbon.[16] In Perilipin A,
lipophile nature is conferred by the slightly hydrophobic amino acids concentrated in the central 25% of the
sequence, region that anchors the protein to the core of the lipid droplet.[17]
Unlike its human ortholog, murine perilipin is composed of 517 amino acids in the primary structure of which several regions can be identified. Three moderately
hydrophobic sequences (H1, H2, H3) of 18 rem (243-260 aa), 23 rem (320-332 aa) and 16 rem (349-364 aa) can be identified in the centre of the protein, as well as an acidic region of 28 residues where both
glutamic and
aspartic acids add up to 19 of them. Five sequences 18 residues long that could form amphipathic β-pleated sheets—according to a prediction made through LOCATE program—are found between aa 111 and 182.[original research?]Serines occupying positions 81, 222, 276, 433, 492 and 517 act as phosphorylation sites -numbered from 1 to 6- for PKA,[18] as well as several other
threonines and
serines which add up to 27 phosphorylation sites.[19]
It controls adipocyte lipid
metabolism.[22] It handles essential functions in the regulation of basal and hormonally stimulated
lipolysis[23] and also rises the formation of large LDs which implies an increase in the synthesis of
triglycerides.[21]
In humans, Perilipin A is the most abundant protein associated with the adipocyte LDs[7] and lower PLIN1 expression is related with higher rates of lipolysis.[24]
In times of energy deficit, Perilipin is
hyperphosphorylated by
PKA following
β-adrenergic receptor activation.[6] Phosphorylated perilipin changes conformation, exposing the stored lipids to hormone-sensitive lipase-mediated lipolysis.
Modulator of adipocyte lipid metabolism
Specifically, in the basal state Perilipin A allows a low level of basal lipolysis[26] by reducing the access of cytosolic lipases to stored triacylglycerol in LDs.[23] It is found at their surface in a complex with CGI-58, the co-activator of ATGL. ATGL might also be in this complex but it is quiescent.[27]
Under lipolytically stimulated conditions, PKA is activated and phosphorylates up to 6
Serine residues on Perilipin A (Ser81, 222, 276, 433, 492, and 517) and 2 on HSL (Ser659, and 660).[27] Although PKA also phosphorylates HSL, which can increase its activity, the more than 50-fold increase in fat mobilization (triggered by
epinephrine) is primarily due to Perilipin phosphorylation[citation needed].
Then, Phosphorylated HSL translocates to the LD surface and associates with Perilipin A and Adipocyte fatty acid-binding protein (AFABP).[27] Consequently, HSL gains access to triacylglycerol (TAG) and diacylglycerol (DAG), substrates in LDs. Also, CGI-58 separates from the LD outer layer which leads to a redistribution of ATGL.[23] In particular, ATGL interacts with Perilipin A through phosphorylated Ser517.[27]
As a result, PKA phosphorylation implies an enriched colocation of HLS and ATGL which facilitates maximal lipolysis by the two lipases.[23]
Clinical significance
Perilipin is an important regulator of lipid storage.[6] Both an overexpression or deficiency of the protein, caused by a mutation, lead to severe health issues.
Overexpression
Perilipin
expression is elevated in
obese animals and humans. Polymorphisms in the human perilipin (PLIN) gene have been associated with variance in body-weight regulation and may be a genetic influence on obesity risk in humans.[28]
This protein can be modified by O-linked acetylglucosamine (
O-GlNac) moieties and the enzyme that intervenes is
O-GlcNAc transferase (OGT). An abundance of OGT obstructs
lipolysis and benefits diet-induced obesity and whole-body insulin resistance. Studies also propose that an overexpression of adipose O-GlcNAc signaling is a molecular expression of obesity and diabetes in humans.[29]
Deficiency
Perilipin-null mice eat more food than
wild-type mice, but gain 1/3 less fat than wild-type mice on the same diet; perilipin-null mice are thinner, with more lean muscle mass.[30] Perilipin-null mice also exhibit enhanced
leptin production and a greater tendency to develop
insulin resistance than wild-type mice. Even though perilipin-null mice present less fat mass and a higher insulin resistance, they do not show signs of a whole lipodystrophic
phenotype.[31]
In humans, studies suggest that a deficiency of PLIN1 causes lipodystrophic syndromes,[32] which disables the optimal accumulation of triglycerides in adipocytes that derives in an abnormal deposition of lipids in tissues such as skeletal muscle and liver. The storage of lipids in the liver leads to insulin resistance and
hypertriglyceridemia. Affected patients are characterized by a subcutaneous fat with smaller than normal adipocytes, macrophage infiltration and
fibrosis.
These findings affirm a new primary form of inherited
lipodystrophy and emphasize on the severe metabolic consequences of a defect in the formation of lipid droplets in adipose tissue.
In particular, variants 13041A>G and 14995A>T have been associated with increased risk of obesity in women and 11482G>A has been associated with decreased perilipin expression and increased lipolysis in women.[33][34]
^
abBrasaemle DL, Subramanian V, Garcia A, Marcinkiewicz A, Rothenberg A (June 2009). "Perilipin A and the control of triacylglycerol metabolism". Molecular and Cellular Biochemistry. 326 (1–2): 15–21.
doi:
10.1007/s11010-008-9998-8.
PMID19116774.
S2CID19802945.
^
abNoureldein MH (2014). "In silico discovery of a perilipin 1 inhibitor to be used as a new treatment for obesity". European Review for Medical and Pharmacological Sciences. 18 (4): 457–60.
PMID24610610.
^Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, et al. (January 2014). "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome". Journal of Proteomics. 96: 253–62.
doi:
10.1016/j.jprot.2013.11.014.
PMID24275569.
^Soenen S, Mariman EC, Vogels N, Bouwman FG, den Hoed M, Brown L, Westerterp-Plantenga MS (March 2009). "Relationship between perilipin gene polymorphisms and body weight and body composition during weight loss and weight maintenance". Physiology & Behavior. 96 (4–5): 723–8.
doi:
10.1016/j.physbeh.2009.01.011.
PMID19385027.
S2CID24747708.
Nishiu J, Tanaka T, Nakamura Y (March 1998). "Isolation and chromosomal mapping of the human homolog of perilipin (PLIN), a rat adipose tissue-specific gene, by differential display method". Genomics. 48 (2): 254–7.
doi:
10.1006/geno.1997.5179.
PMID9521880.
Qi L, Corella D, Sorlí JV, Portolés O, Shen H, Coltell O, et al. (October 2004). "Genetic variation at the perilipin (PLIN) locus is associated with obesity-related phenotypes in White women". Clinical Genetics. 66 (4): 299–310.
doi:
10.1111/j.1399-0004.2004.00309.x.
PMID15355432.
S2CID24420287.
Qi L, Tai ES, Tan CE, Shen H, Chew SK, Greenberg AS, et al. (June 2005). "Intragenic linkage disequilibrium structure of the human perilipin gene (PLIN) and haplotype association with increased obesity risk in a multiethnic Asian population". Journal of Molecular Medicine. 83 (6): 448–56.
doi:
10.1007/s00109-004-0630-4.
PMID15770500.
S2CID7820923.
Forcheron F, Legedz L, Chinetti G, Feugier P, Letexier D, Bricca G, Beylot M (August 2005). "Genes of cholesterol metabolism in human atheroma: overexpression of perilipin and genes promoting cholesterol storage and repression of ABCA1 expression". Arteriosclerosis, Thrombosis, and Vascular Biology. 25 (8): 1711–7.
CiteSeerX10.1.1.581.2332.
doi:
10.1161/01.ATV.0000174123.19103.52.
PMID15961705.
S2CID5150107.
Shimizu M, Akter MH, Emi Y, Sato R, Yamaguchi T, Hirose F, Osumi T (March 2006). "Peroxisome proliferator-activated receptor subtypes differentially cooperate with other transcription factors in selective transactivation of the perilipin/PEX11 alpha gene pair". Journal of Biochemistry. 139 (3): 563–73.
doi:
10.1093/jb/mvj053.
PMID16567422.